{"analyses":[{"ciLowerLimit":"0.97","ciPctValue":"95","ciUpperLimit":"2.12","estimateComment":"Temozolomide numerator (responders) = 55. Dacarbazine numerator (responders) = 37.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0718","paramType":"Odds Ratio (OR)","paramValue":"1.43","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"0.17","value":"0.14"},{"groupId":"OG001","lowerLimit":"0.07","upperLimit":"0.12","value":"0.10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"401"},{"groupId":"OG001","value":"388"}],"units":"Participants"}],"description":"Based on investigator's assessment of response in subjects with measurable lesions. Objective response = complete response + partial response. Complete response = disappearance of all target lesions. Partial response = at least a 30% decrease in the sum of longest diameter of target lesions taking as reference the baseline sum longest diameter.","dispersionType":"95% Confidence Interval","groups":[{"description":"temozolomide 150 mg/m2/day PO, on 7 consecutive days every 14 days (\"7 days on / 7 days off\" continuously)","id":"OG000","title":"Temozolomide"},{"description":"dacarbazine 1000 mg/m2 IV, on Day 1 +/- 3 days every 3 weeks","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population with measurable disease at Baseline.","reportingStatus":"POSTED","timeFrame":"Treatment continued until disease progression or unacceptable toxicity.","title":"Objective Response Rate in Subjects With Measurable Lesions","type":"SECONDARY","unitOfMeasure":"Ratio"}